Category Archives: MS Treatment

19-06-2012 11:39 It's tragic to be sure, even if it takes a celebrity to bring the problem to light. Jack Osbourne - son of pop singer Ozzy Osbourne - was diagnosed with multiple sclerosis several days ago. As is likely the case with any newly-diagnosed MS sufferer, the question he soon began as king is, "Now what?" The answer was, though brave, also obvious... begin treatments, and fight. Unfortunately, Osbourne soon found out what the United States' 400000 multiple sclerosis patients (and the world's 2.5 million MS patients) already know too well... there is no cure, and treatment options aren't all that great either. That may not be the case for much longer, however. Though a true 'cure' isn't on the table yet, some treatments are proving to be effective, and a cure isn't out of the question.One of the more effective treatments us a drug called Fampyra, jointly made by Biogen Idec (NASDAQ:BIIB) and Acorda Therapeutics Inc. (NASDAQ:ACOR). Though the drug was approved for specific use - to improve casual walking in multiple sclerosis patients - in the United States a couple of years ago, it was only approved for the same use in Europe late last month. It's … Continue reading →

18-06-2012 00:51 Watch on above and read the reviews below to see what our Trial Teamers thought after road-testing this treatment conditioner... Find out more: Originally posted here: Dove Daily Treatment Conditioner review - Platinum Ms - Video … Continue reading →

Jack Osbourne, reality TV star and son of rock god Ozzy Osbourne, told People magazine that he has been diagnosed with multiple sclerosis. The long-term outlook for Osbourne's health, however, apparently is not nearly as dire as the news might suggest. Treatment for symptoms is available that could allow Osbourne to lead a full life with few complications, despite MS, some doctors say. "I was just angry and frustrated and kept thinking, 'Why now?'" Osbourne, 26, said. "I've got a family and that's what's supposed to be the most important thing." The news came two weeks after his fiance Lisa Stelly gave birth to their daughter Pearl Clementine. Osbourne said he noticed that he lost most of his vision in his right eye. "The timing was so bad", Jack told HELLO! Magainze. "I'd just had a baby, work was going great ... I kept thinking: 'Why now?'" Follow us Multiple sclerosis is an autoimmune disease that attacks the central nervous system, which has no known cure. Its symptoms include difficulties in vision, loss of muscle control, balance and in severe cases, paralysis. It is usually diagnosed in people in their 20s, and 30s. There are 200 new cases of MS … Continue reading →

Innate Immunotherapeutics MS drug to go to second trial Auckland, NZ, June 19 2012: New Zealand biopharmaceutical company Innate Immunotherapeutics says trials of its drug to help people with chronic, progressive multiple sclerosis (MS) are showing positive results. Simon Wilkinson, chief executive of Innate Immunotherapeutics, says results of the Phase 1/2 clinical trial have shown MIS416 to be well tolerated and identified a clinical dose for further evaluation. MIS416 is the lead product from the Auckland-based biopharmas proprietary immune modulating microparticle technology. Neurologist Professor Tim Anderson, co-principal investigator for the study, says the preliminary data indicate that MIS416 was safe and well tolerated. The MS-related clinical status assessment tools used during the study also indicate that the trial agent may have had some positive effect for many of the treated patients. During the dose confirmation portion of the study, eight of 10 patients with secondary progressive MS treated with MIS416 for 12 weeks showed some improvement in their MS-related signs and symptoms. For example, 50% of the study subjects showed some improvement in EDSS scores over the relatively short 12 week duration of the trial, Professor Anderson says. These interim results are encouraging and merit the consideration of a randomised, … Continue reading →

More Topics: Choose a Sector Accounting Firms Advertising/Media/Communications Capital CEO/Board General Business Health/Biotech Internet/Technology Investment Firms Law Firms Mergers & Acquisitions Money Managers People Private Companies Public Companies Venture Capital Posted June 18, 2012 MILL SPRING, N.C., -- The National Association of Addiction Treatment Providers, (NAATP) has elected Anne Vance of Pavillon Treatment Center in North Carolina to its board of directors. Ms. Vance is CEO of the 80-bed not-for-profit residential and outpatient center in Western North Carolina, about 45 minutes from Asheville. She represents one of few women elected to the 20-member board. Pavillon is a nationally recognized addiction treatment and recovery center, having successfully treated hundreds of individuals and families from around the nation and overseas since 1996. Board members are elected by a team of peers and fellow members, representing over 830 individuals from around the nation. All officers serve a three-year term. "Since it is often the administrator or CEO who creates and sustains the vision of a treatment center, it is significant that Anne has achieved this deserved honor. She will continue to effectively represent Pavillon and the addiction treatment industry as well as she has for many years," said Bob Hayes, Jr., board chairman … Continue reading →

17 June 2012 Last updated at 22:58 ET By Dominic Hughes Health correspondent, BBC News New research suggests the number of children suffering from multiple sclerosis may be higher than previously thought. It remains a very rare condition and only a third of young people who have an attack will go on to develop MS in later life. But it can have a devastating affect on children and their families. One of those is 15-year-old Emily Murdoch from Cannock in Staffordshire. Like many girls her age, she loves horses and has been riding since she was a little girl. One day she hopes to represent Britain in competition, but she does not know if it will be in the Olympics or Paralympics. At the age of 12, Emily was diagnosed with childhood multiple sclerosis. An attack can leave her confined to a wheelchair when her legs stop working. She suffers from severe tiredness, muscle spasms and numb hands and legs. "It's not really very nice," she says "especially when my legs go on me, because it's the second time my legs have gone on me." View post: "My battle against childhood MS" … Continue reading →

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced that the company has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) and a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval of LEMTRADA (alemtuzumab) for treatment of relapsing multiple sclerosis (RMS). Genzyme is developing LEMTRADA in MS in collaboration with Bayer HealthCare. Genzymes clinical development program for LEMTRADA included two Phase III studies in which results for LEMTRADA were superior to Rebif (high dose subcutaneous interferon beta-1a) on clinical and imaging endpoints, including a reduction in relapse rate. In addition, as presented last month at the American Academy of Neurology meeting, some patients with pre-existing disability treated with LEMTRADA in the CARE-MS II trial were more than twice as likely to experience a sustained reduction in disability over two years than patients treated with Rebif. There remains a large unmet treatment need for patients living with active disease and we believe that LEMTRADA, given its efficacy and unique dosing schedule, has the potential to transform the lives of patients with MS, said Genzyme President and CEO, David Meeker. The regulatory submissions for LEMTRADA include … Continue reading →

(RTTNews.com) - Swiss drugmaker Novartis AG (NVS) on Monday said a new data for multiple sclerosis drug Gilenya (fingolimod) showed long-term efficacy benefit and a consistent safety profile. Gilenya, licensed from Japan'sMitsubishi Tanabe Pharma Corp., is the only oral therapy approved to treat people with relapsing forms of multiple sclerosis. The data from single-arm extension of phase III head-to-head TRANSFORMS study showed sustained reduction in relapses and rate of brain volume loss in patients on continuous Gilenya treatment for up to 4.5 years, the company noted The results also showed improved efficacy for patients switched to Gilenya from Avonex (interferon-beta-1a IM), a commonly prescribed MS treatment from Biogen Idec Inc. (BIIB). Novartis noted that reductions in relapses and MRI measures were observed in these patients. In the core TRANSFORMS study, Gilenya demonstrated superior efficacy to Avonex, reducing the annualized relapse rate by 52% at one year. The extension study showed that this low relapse rate was sustained in patients receiving continuous treatment with Gilenya for up to 4.5 years. As per the study results, patients treated with Gilenya continuously maintained a low brain atrophy rate throughout the study as measured by assessing brain volume loss, which is valued as a … Continue reading →

CNW Group/Novartis Pharmaceuticals Canada Inc. Caitlin Cronenbergis a young photographer who has made a name for herself chronicling fashion and celebrityas well as the cinematic process of her filmmaker father, David Cronenberg. So a press release issued last week headlined Caitlin Cronenberg Exposes the Reality of Young Women Living with MS appeared to signal a boldeven bravedeparture for her. Multiple sclerosis, or MS, is a chronic degenerative condition that can lead to paralysis, depression, and blindness. Its a mysterious condition; progression varies radically; its cause is unknown. Nobody even knows how many Canadians have it: the much-repeated statistic of 50,000 to 75,000 people is out of date, an MS Society of Canada spokesperson told me months ago. It doesnt lend to easy imagery. So I wondered: Is Cronenberg now delving into the dark, uncomfortable territory annexed so well by her dad? But the reality that Cronenbergs one-night exhibit, DREAM/AWAKE, exposes is less about MS than about how a pharmaceutical giant can create buzz amid advertising restrictionsin this case, by linking a fashionable female photographer to a prescription drug targeted at young women. Thats whom multiple sclerosis strikes mostthree times more frequently than men. Cronenberg was hired for the gig a … Continue reading →

Patients who underwent the so-called liberation treatment for multiple sclerosis experienced no measurable benefit from the procedure, a study commissioned by the government of Newfoundland and Labrador found. The results of the small, observational study were announced in St. John's by lead investigator Dr. William Pryse-Phillips, a professor emeritus of neurology at Newfoundland's Memorial University. Pryse-Phillips said he had gone into the study hopeful the treatment might have something to offer his MS patients, but completed it convinced the people who had the vein-opening procedure didn't experience any gains. "I am disappointed. I had hoped. I cannot recommend this therapy on the basis of these results at this time," he said during a news conference on Wednesday, the video of which is posted on the Department of Health and Community Service's website. The province spent $400,000 on the study, which compared 30 patients with MS who had travelled outside the province to have the therapy and 10 who did not. Participants were subjected to an array of tests before the treatment and then at intervals of one month, three months, six months and one year post-procedure. Saskatchewan's government is spending $2.2 million to help fund an Albany, N.Y.-based clinical trial … Continue reading →